ClinicalTrials.gg
RecruitingNCT07732400RESTOREUpdated Sep 1, 2026

A Study of VV-14303 for the Treatment of Metabolic Dysfunction-associated Steatohepatitis (MASH)

A Phase 1/2 interventional study of VV-14303 in Metabolic Dysfunction-associated Steatohepatitis (MASH), sponsored by Kriya Therapeutics, Inc.. Recruiting at 3 sites in 2 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-09-01.

Sponsored by Kriya Therapeutics, Inc. · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jul 2026; still recruiting 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
56
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 212 studies in Fatty Liver with a site in United States — 42 open to participants now, 48 under way, 8 of them phase 3. Fatty Liver · United States.

Planned enrollment
70th of 163
56 · median 44
Started
2026
with 14 others
Phase 1/2
12 of 212
3 open now
Primary completion
2028-07
later than 29 of 47 live
Registered
206th of 212
by date

Among the 212 studies in Fatty Liver with a site in United States, this one is the 70th largest by planned enrollment of the 163 interventional ones that give a count, is one of 15 that started in 2026, is one of 12 in phase 1/2, reaches primary completion later than 29 of the 47 other live ones, and was the 206th registered.

Fatty Liver

666 studies on the registry are indexed under Fatty Liver; 188 are open to participants now.

Browse Fatty Liver studies →

Open to participants now

42 of the 212 studies in Fatty Liver with a site in United States are open now. Recruiting first, the newest first:

36 more — sign in →

All 42 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 118 Fatty Liver studies recruiting now, 36 (31%) set no upper age limit and 63 (53%) stop at 75 or younger; 8 take children under 18; 32 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 212 studies in Fatty Liver with a site in United States, or all of them as a file.
02

Study summary

A Study of VV-14303 for the Treatment of Metabolic dysfunction-associated steatohepatitis (MASH)

Read the detailed description

A Phase 1/2, First-in-Human, Multi-Arm, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of VV-14303, an Adeno-associated Virus Vector-mediated Fibroblast Growth Factor 21 (FGF21) Gene Therapy, in Adults with Metabolic dysfunction associated steatohepatitis (MASH) (the RESTORE Study)

03

Conditions studied

  • Metabolic Dysfunction-associated Steatohepatitis (MASH)

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant is capable of providing signed , which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in the protocol
  • Must be 18 to 75 years of age (inclusive) at Screening
  • (BMI) of 25 to \<40 kg/m2 (inclusive)
  • Male participants must agree to use a highly effective during the Treatment Period and at least 12 months after administration of VV-14303. Female participants must not be a woman of (WOCBP)
  • -confirmed MASH
  • Previous history or presence of ≥2 of the following metabolic risk factors: obesity (BMI ≥25 kg/m²), hypertension (blood pressure [BP] ≥140/90 mmHg or on antihypertensive medication), dyslipidemia (triglycerides ≥150 mg/dL or high-density lipoprotein cholesterol [HDL-C] \<40 mg/dL in men/\<50 mg/dL in women or on lipid-lowering therapy), type 2 diabetes mellitus
  • Must be willing to refrain from the donation of blood, plasma, , eggs, or sperm during the 12-month post-treatment follow-up period

Exclusion criteria

Exclusion Criteria:

  • Presence of alternate and/or additional liver disease etiologies at Screening, including but not limited to chronic viral hepatitis, hepatitis
  • Use of treatments for metabolic syndrome management, including oral antidiabetic drugs (OADs) (e.g., metformin), incretin mimetics (GLP-1 receptor agonists or GLP-1/gastric inhibitory polypeptide [GIP] agonists) or other glucose-lowering agents that has not been stable for at least 6 months prior to Screening
  • Use of Resmetirom that has not been stable for at least 6 months prior to Screening visit
  • Any medical, cognitive, or psychiatric condition that, in the opinion of the Investigator, could contraindicate the use of the drug, make consistent study assessment and follow-up over the 12-month Post-Treatment Follow-up Period unlikely, or would make the participant an unsafe study candidate.
  • Type 1 diabetes, or poorly controlled type 2 diabetes ( > 8.0% at Screening)
  • History of major trauma to the muscle(s) intended for IM injection meeting any of the following criteria:

    1. Within 6 months prior to Screening, or
    2. At any timepoint prior to Screening with continued neurologic or musculoskeletal symptoms
  • Prior participation in any systemic experimental treatment or receiving any other systemic investigational treatment including within 6 weeks or 5 half-lives of the active ingredient (whichever is longer) prior to the start of Screening
  • Any vaccination or planned vaccination 30 days prior to dosing, or planned vaccination 8 weeks post dosing
  • Previously received AAV or adenoviral therapy or participation in any previous gene therapy trial
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
56 participants (estimated)

Study arms

  • Experimental
    Part 1 Cohort 1, dose #1

    Dose #1 of VV-14303 will be administered

    Genetic: VV-14303

  • Experimental
    Part 1 Cohort 2, dose #2

    Dose #2 of VV-14303 will be administered

    Genetic: VV-14303

  • Experimental
    Part 1 Cohort 3, dose #3

    Dose #3 of VV-14303 will be administered

    Genetic: VV-14303

  • Experimental
    Part 2 dose

    VV-14303 will be administered at the dose determined from Part 1 (Cohorts 1, 2, and 3)

    Genetic: VV-14303

Interventions

  • GeneticVV-14303

    will be administered via ultrasound guided intramuscular injections

06

What researchers measure

Primary outcomes

  1. Incidence and severity of adverse events, abnormal clinical laboratory values, abnormal physical exams, abnormal vital signs, abnormal ECGs, and abnormal imaging

    Safety of VV-14303 in participants with MASH

    Time frame: 52 Weeks

  2. Number of participants with improvement in overall metabolic health, as assessed by changes in serum biomarker levels

    Evaluate safety and efficacy of VV-14303 in participants with MASH in Part 1

    Time frame: 6 weeks

  3. Changes in liver fat content as assessed by Magnetic Resonance Proton Density Fat Fraction (MRI-PDFF) as assessed by FibroScan®

    Efficacy of VV-14303 in participants with MASH in Part 2

    Time frame: 26 Weeks

  4. Change in liver fat content as assessed by controlled attenuation parameter (CAP) as assessed by FibroScan®

    Efficacy of VV-14303 in participants with MASH in Part 2

    Time frame: 26 weeks

Secondary outcomes

  1. Efficacy associated with VV-14303 in participants with MASH

    Liver stiffness as measured by change from Baseline transient elastography as assessed by FibroScan®

    Time frame: Week 26 and 52

  2. Efficacy associated with VV-14303 in participants with MASH

    Liver stiffness as measured by change from Baseline in Magnetic Resonance Elastography (MRE)

    Time frame: Week 26 and 52

  3. Efficacy associated with VV-14303 in participants with MASH

    Mean changes in liver fat content as assessed by MRI-PDFF as assessed by FibroScan®

    Time frame: 52 Weeks

  4. Efficacy associated with VV-14303 in participants with MASH

    Mean changes in liver fat content as assessed by CAP as assessed by FibroScan®

    Time frame: 52 Weeks

  5. Part 1: Efficacy associated with VV-14303 in participants with MASH

    Mean changes in liver fat content as assessed by MRI-PDFF as assessed by FibroScan®

    Time frame: 26 Weeks

  6. Part 1: Efficacy associated with VV-14303 in participants with MASH

    Mean changes in liver fat content as assessed by CAP as assessed by FibroScan®

    Time frame: 26 Weeks

  7. Concentration of adeno-associated virus (AAV) vector-mediated transgene product in serum

    Pharmacokinetics of VV-14303 transgene product

    Time frame: 52 Weeks

07

Study locations

1 of 3 sites recruiting
  • Kriya Clinical Trial Site
    Chandler, Arizona 85224, United States
    Not yet recruiting
  • Kriya Clinical Trial Site
    Lady Lake, Florida 32159, United States
    Recruiting
  • Kriya Clinical Trial Site
    Auckland, New Zealand
    Not yet recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2026 (actual). Primary completion is estimated for Jul 2028, 24 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 14, 2026
First posted
Jul 28, 2026
StartActual
Jul 30, 2026
Primary completionEst.
Jul 2028
CompletionEst.
Jul 2029
Last update
Sep 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07732400
Responsible party
Sponsor
First posted
Jul 28, 2026
Start date
Jul 30, 2026
Primary completion
Jul 2028 (estimated)
Completion
Jul 2029 (estimated)
Last update
Sep 1, 2026

Study contacts

VP, Medical Affairs
Contact
clinicaltrials@kriyatx.com
1.984.884.5058

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion